Abstract: The present invention provides a preparation of a Siglec-15 binding protein and the use thereof, and specifically relates to an isolated antigen-binding protein, which comprises HCDR3. Provided is the use of the antigen-binding protein in the prevention and treatment of diseases.

Abstract: Provided is an GARP protein antibody, and a cell comprising or expressing the GA RP protein antibody. The GARP protein antibody binds to human GARP/human TGF-?1 complex with a KD value of about 1.0E-12 or less. Also provided are a pharmaceutical combination comprising the GARP protein antibody and an immune checkpoint inhibitor and use thereof.

Abstract: A group of viral vectors including: first viral vector, wherein first viral vector carries first nucleic acid molecule, and the first nucleic acid molecule encodes envelope protein; second viral vector, wherein second viral vector carries second nucleic acid molecule, the second nucleic acid molecule encodes fusion protein, the fusion protein includes single-chain antibody and C-terminal domain of envelope protein, the C-terminal domain of envelope protein includes transmembrane region and intracellular region of envelope protein, the C-terminus of single-chain antibody connects with N-terminus of C-terminal domain of envelope protein, the single-chain antibody targets a specific antigen; first nucleic acid molecule and second nucleic acid molecule are arranged to express envelope protein and fusion protein, and the envelope protein and the fusion protein are in non-fusion form.